| pubmed-article:21709185 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:21709185 | lifeskim:mentions | umls-concept:C0281361 | lld:lifeskim |
| pubmed-article:21709185 | lifeskim:mentions | umls-concept:C0242656 | lld:lifeskim |
| pubmed-article:21709185 | lifeskim:mentions | umls-concept:C1559154 | lld:lifeskim |
| pubmed-article:21709185 | lifeskim:mentions | umls-concept:C0694891 | lld:lifeskim |
| pubmed-article:21709185 | lifeskim:mentions | umls-concept:C0069717 | lld:lifeskim |
| pubmed-article:21709185 | lifeskim:mentions | umls-concept:C1517927 | lld:lifeskim |
| pubmed-article:21709185 | lifeskim:mentions | umls-concept:C0045093 | lld:lifeskim |
| pubmed-article:21709185 | lifeskim:mentions | umls-concept:C0995188 | lld:lifeskim |
| pubmed-article:21709185 | lifeskim:mentions | umls-concept:C0282460 | lld:lifeskim |
| pubmed-article:21709185 | lifeskim:mentions | umls-concept:C1707520 | lld:lifeskim |
| pubmed-article:21709185 | lifeskim:mentions | umls-concept:C0332283 | lld:lifeskim |
| pubmed-article:21709185 | lifeskim:mentions | umls-concept:C0449774 | lld:lifeskim |
| pubmed-article:21709185 | lifeskim:mentions | umls-concept:C0205179 | lld:lifeskim |
| pubmed-article:21709185 | pubmed:issue | 22 | lld:pubmed |
| pubmed-article:21709185 | pubmed:dateCreated | 2011-7-29 | lld:pubmed |
| pubmed-article:21709185 | pubmed:abstractText | This phase II trial was designed to assess the efficacy and safety of cetuximab, gemcitabine, and oxaliplatin followed by cetuximab, capecitabine, and radiation therapy in locally advanced pancreatic cancer (LAPC). | lld:pubmed |
| pubmed-article:21709185 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21709185 | pubmed:language | eng | lld:pubmed |
| pubmed-article:21709185 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21709185 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:21709185 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21709185 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21709185 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21709185 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21709185 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21709185 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21709185 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21709185 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21709185 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21709185 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:21709185 | pubmed:month | Aug | lld:pubmed |
| pubmed-article:21709185 | pubmed:issn | 1527-7755 | lld:pubmed |
| pubmed-article:21709185 | pubmed:author | pubmed-author:AbbruzzeseJam... | lld:pubmed |
| pubmed-article:21709185 | pubmed:author | pubmed-author:WolffRobert... | lld:pubmed |
| pubmed-article:21709185 | pubmed:author | pubmed-author:CraneChristop... | lld:pubmed |
| pubmed-article:21709185 | pubmed:author | pubmed-author:SafranHowardH | lld:pubmed |
| pubmed-article:21709185 | pubmed:author | pubmed-author:LeeJeffrey... | lld:pubmed |
| pubmed-article:21709185 | pubmed:author | pubmed-author:DasPrajnanP | lld:pubmed |
| pubmed-article:21709185 | pubmed:author | pubmed-author:FlemingJason... | lld:pubmed |
| pubmed-article:21709185 | pubmed:author | pubmed-author:KrishnanSunil... | lld:pubmed |
| pubmed-article:21709185 | pubmed:author | pubmed-author:StaerkelGregg... | lld:pubmed |
| pubmed-article:21709185 | pubmed:author | pubmed-author:YordyJohn SJS | lld:pubmed |
| pubmed-article:21709185 | pubmed:author | pubmed-author:JavleMilind... | lld:pubmed |
| pubmed-article:21709185 | pubmed:author | pubmed-author:VaradhacharyG... | lld:pubmed |
| pubmed-article:21709185 | pubmed:author | pubmed-author:HaqueWaqarW | lld:pubmed |
| pubmed-article:21709185 | pubmed:author | pubmed-author:HobbsBridgett... | lld:pubmed |
| pubmed-article:21709185 | pubmed:issnType | Electronic | lld:pubmed |
| pubmed-article:21709185 | pubmed:day | 1 | lld:pubmed |
| pubmed-article:21709185 | pubmed:volume | 29 | lld:pubmed |
| pubmed-article:21709185 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:21709185 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:21709185 | pubmed:pagination | 3037-43 | lld:pubmed |
| pubmed-article:21709185 | pubmed:dateRevised | 2011-8-30 | lld:pubmed |
| pubmed-article:21709185 | pubmed:meshHeading | pubmed-meshheading:21709185... | lld:pubmed |
| pubmed-article:21709185 | pubmed:meshHeading | pubmed-meshheading:21709185... | lld:pubmed |
| pubmed-article:21709185 | pubmed:meshHeading | pubmed-meshheading:21709185... | lld:pubmed |
| pubmed-article:21709185 | pubmed:meshHeading | pubmed-meshheading:21709185... | lld:pubmed |
| pubmed-article:21709185 | pubmed:meshHeading | pubmed-meshheading:21709185... | lld:pubmed |
| pubmed-article:21709185 | pubmed:meshHeading | pubmed-meshheading:21709185... | lld:pubmed |
| pubmed-article:21709185 | pubmed:meshHeading | pubmed-meshheading:21709185... | lld:pubmed |
| pubmed-article:21709185 | pubmed:meshHeading | pubmed-meshheading:21709185... | lld:pubmed |
| pubmed-article:21709185 | pubmed:meshHeading | pubmed-meshheading:21709185... | lld:pubmed |
| pubmed-article:21709185 | pubmed:meshHeading | pubmed-meshheading:21709185... | lld:pubmed |
| pubmed-article:21709185 | pubmed:meshHeading | pubmed-meshheading:21709185... | lld:pubmed |
| pubmed-article:21709185 | pubmed:meshHeading | pubmed-meshheading:21709185... | lld:pubmed |
| pubmed-article:21709185 | pubmed:meshHeading | pubmed-meshheading:21709185... | lld:pubmed |
| pubmed-article:21709185 | pubmed:meshHeading | pubmed-meshheading:21709185... | lld:pubmed |
| pubmed-article:21709185 | pubmed:meshHeading | pubmed-meshheading:21709185... | lld:pubmed |
| pubmed-article:21709185 | pubmed:meshHeading | pubmed-meshheading:21709185... | lld:pubmed |
| pubmed-article:21709185 | pubmed:meshHeading | pubmed-meshheading:21709185... | lld:pubmed |
| pubmed-article:21709185 | pubmed:meshHeading | pubmed-meshheading:21709185... | lld:pubmed |
| pubmed-article:21709185 | pubmed:meshHeading | pubmed-meshheading:21709185... | lld:pubmed |
| pubmed-article:21709185 | pubmed:meshHeading | pubmed-meshheading:21709185... | lld:pubmed |
| pubmed-article:21709185 | pubmed:meshHeading | pubmed-meshheading:21709185... | lld:pubmed |
| pubmed-article:21709185 | pubmed:meshHeading | pubmed-meshheading:21709185... | lld:pubmed |
| pubmed-article:21709185 | pubmed:meshHeading | pubmed-meshheading:21709185... | lld:pubmed |
| pubmed-article:21709185 | pubmed:meshHeading | pubmed-meshheading:21709185... | lld:pubmed |
| pubmed-article:21709185 | pubmed:year | 2011 | lld:pubmed |
| pubmed-article:21709185 | pubmed:articleTitle | Phase II trial of cetuximab, gemcitabine, and oxaliplatin followed by chemoradiation with cetuximab for locally advanced (T4) pancreatic adenocarcinoma: correlation of Smad4(Dpc4) immunostaining with pattern of disease progression. | lld:pubmed |
| pubmed-article:21709185 | pubmed:affiliation | Dept of Radiation Oncology, Unit 97, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX. ccrane@mdanderson.org | lld:pubmed |
| pubmed-article:21709185 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:21709185 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| pubmed-article:21709185 | pubmed:publicationType | Clinical Trial, Phase II | lld:pubmed |
| pubmed-article:21709185 | pubmed:publicationType | Research Support, N.I.H., Extramural | lld:pubmed |
| entrez-gene:4089 | entrezgene:pubmed | pubmed-article:21709185 | lld:entrezgene |
| http://linkedlifedata.com/r... | entrezgene:pubmed | pubmed-article:21709185 | lld:entrezgene |
